Uro-oncology research group
urinoids, prostate, diagnostics
Research aim
Pioneering precise diagnostics in urologic oncology research, employing cutting-edge imaging modalities and genetic profiling for early detection and personalized treatment strategies, revolutionizing patient care and outcomes.
About us
At the forefront of urologic oncology, our research group harnesses cutting-edge technologies to advance diagnostics. Integrating AI into pathology analysis, we enhance accuracy and efficiency in tumor classification and prognostication.
In bladder cancer, we pioneer the use of urine-based bladder cancer organoids (urinoids) to advance insight in tumor pathogenesis and drug-resistance development during treatment and for drug-response evaluation.
Furthermore, with the ‘Dutch Prospective Bladder Cancer Infrastructure’ (ProBCI), we aim to establish a nation-wide cohort of bladder cancer patients serving as an efficient starting point for observational research with readily available extensive clinical data reflecting daily clinical practice, PROMs and biomaterial.
For testicular cancer, we employ radiomics to extract quantitative imaging features, enabling precise tumor characterization and treatment response assessment. By synergizing expertise across disciplines, including pathology, radiology, and molecular biology, we unlock new insights into disease mechanisms and therapeutic targets. Through continuous innovation and collaboration, we strive to redefine diagnostic standards, empowering clinicians with tailored insights for personalized treatment strategies. Our commitment to advancing precision medicine ensures that patients receive timely interventions and optimized outcomes in their fight against urologic malignancies.